Lixte Biotechnology Holdings, Inc. develops tests for the detection of cancers in the United States. Its tests are used for the estimation of prognosis, monitoring of treatment response, and to reveal targets for development of treatments. The company focuses on the discovery of biomarkers for common cancers that would enable identification of the presence of cancer at a stage curable by surgery. It also focuses on the development of new treatments for primary brain cancer, glioblastoma multiforme. The company has a cooperative research and development agreement with National Institute of Neurological Diseases and Stroke of the National Institutes of Health to identify and evaluate drugs that target a specific biochemical pathway for GBM cell differentiation. Lixte Biotechnology Holdings was incorporated in 2005 and is based in East Setauket, New York.
Lixte Biotechnology Holdings, Inc.
248 Route 25A
East Setauket, NY 11733